MA54719A - Composition pharmaceutique pour réduire les toxines urémiques liées aux protéines - Google Patents

Composition pharmaceutique pour réduire les toxines urémiques liées aux protéines

Info

Publication number
MA54719A
MA54719A MA054719A MA54719A MA54719A MA 54719 A MA54719 A MA 54719A MA 054719 A MA054719 A MA 054719A MA 54719 A MA54719 A MA 54719A MA 54719 A MA54719 A MA 54719A
Authority
MA
Morocco
Prior art keywords
pharmaceutical composition
uremic toxins
reducing protein
bound uremic
bound
Prior art date
Application number
MA054719A
Other languages
English (en)
Inventor
Alpesh Chhunchha
Ankit Shyam
Original Assignee
Frimline Private Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frimline Private Ltd filed Critical Frimline Private Ltd
Publication of MA54719A publication Critical patent/MA54719A/fr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/733Fructosans, e.g. inulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716Glucans
    • A61K31/718Starch or degraded starch, e.g. amylose, amylopectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/2004Excipients; Inactive ingredients
    • A61K9/2022Organic macromolecular compounds
    • A61K9/205Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806Coating materials
    • A61K9/2833Organic macromolecular compounds
    • A61K9/286Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841Filling excipients; Inactive ingredients
    • A61K9/4866Organic macromolecular compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
MA054719A 2020-01-27 2021-01-25 Composition pharmaceutique pour réduire les toxines urémiques liées aux protéines MA54719A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN202021003641 2020-01-27

Publications (1)

Publication Number Publication Date
MA54719A true MA54719A (fr) 2021-11-17

Family

ID=74661416

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054719A MA54719A (fr) 2020-01-27 2021-01-25 Composition pharmaceutique pour réduire les toxines urémiques liées aux protéines

Country Status (10)

Country Link
US (1) US12048713B2 (fr)
EP (1) EP3908260B1 (fr)
AU (1) AU2021214954B2 (fr)
CA (1) CA3130438C (fr)
CO (1) CO2021016583A2 (fr)
MA (1) MA54719A (fr)
PE (1) PE20221660A1 (fr)
PH (1) PH12021552416A1 (fr)
UA (1) UA128706C2 (fr)
WO (1) WO2021152441A1 (fr)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0101459D0 (en) * 2001-01-19 2001-03-07 Uni Vite Exp Ltd Nutritional composition
CN1504229A (zh) 2002-12-05 2004-06-16 王永山 治疗慢肾衰、尿毒症的免疫排毒粉
FR2851425A1 (fr) * 2003-02-21 2004-08-27 Oligocaps Lab Complement nutritionnel a base de chitosan ayant une composition original sous diverses formes galeniques
US7198785B2 (en) 2003-12-09 2007-04-03 Brown University Systems and methods related to degradation of uremic toxins
TWI481409B (zh) 2013-01-10 2015-04-21 Conmed Pharmaceutical & Bio Medical Corp 一種使用益生菌製備用於清除尿毒素之組合物的用途
MX367504B (es) 2013-03-21 2019-07-31 Nutrimentos Inteligentes S A De C V Mezcla gelatinosa de probióticos y prebióticos con acción simbiótica sinérgica para el tratamiento de enfermedad renal crónica.
CN104740611B (zh) 2015-04-13 2017-04-12 江西康宝医药生物科技有限公司 一种治疗尿毒症的中药组合物及其制备方法
WO2018125693A1 (fr) * 2016-12-27 2018-07-05 Hill's Pet Nutrition, Inc. Compositions alimentaires pour animaux de compagnie et méthodes associées
CA3067991A1 (fr) * 2017-06-26 2019-01-03 Kibow Biotech, Inc. Procedes de maintien et d'amelioration de la fonction renale chez des patients atteints d'une maladie renale et suivant une therapie de soins standard

Also Published As

Publication number Publication date
AU2021214954A1 (en) 2021-09-02
CA3130438A1 (fr) 2021-08-05
AU2021214954B2 (en) 2023-06-29
US20220370492A1 (en) 2022-11-24
EP3908260B1 (fr) 2022-09-21
CA3130438C (fr) 2023-08-01
WO2021152441A1 (fr) 2021-08-05
PH12021552416A1 (en) 2022-07-11
EP3908260A1 (fr) 2021-11-17
CO2021016583A2 (es) 2022-01-17
US12048713B2 (en) 2024-07-30
PE20221660A1 (es) 2022-10-26
UA128706C2 (uk) 2024-10-02

Similar Documents

Publication Publication Date Title
MA47604A (fr) Anticorps anti-pd-1 pour le traitement du cancer du poumon
EP3549588A4 (fr) Composition pharmaceutique pour prévenir ou traiter le cancer du foie, comprenant un polymorphe cristallin d'hexaoxyde de tétra-arsenic
EP3849643A4 (fr) Joint nasal pour interface patient respiratoire
BR112022014306A2 (pt) Anticorpo anti-angptl3 e uso do mesmo
EP4153285A4 (fr) Casque pour interface patient
GB202213827D0 (en) Ue initiated model-updates for two-sided ai/ml model
MA54719A (fr) Composition pharmaceutique pour réduire les toxines urémiques liées aux protéines
EP3708173A4 (fr) COMPOSITION PHARMACEUTIQUE THÉRAPEUTIQUE POUR LE CANCER COMPRENANT UN miARN
IL282091A (en) System and method for removing uremic toxins from a patient's body
SG11202102616PA (en) Method and composition for removing uremic toxins
IL287392A (en) New compounds and their pharmaceutical preparations for the treatment of kidney diseases
EP3743072A4 (fr) Composition pharmaceutique pour administration à libération prolongée de buprénorphine
EP4144371A4 (fr) Médicament combiné pour le traitement du cancer du rein
EP4349349A4 (fr) Composition pharmaceutique contenant des fibroblastes pour le traitement d'une maladie rénale
EP3881856A4 (fr) Composition pharmaceutique destinée au traitement de l'anémie aplasique
AU2022214501A9 (en) Pharmaceutical composition for treating liver diseases using ssu72
EP4174087A4 (fr) Médicament pour le traitement de tumeur
EP4130025A4 (fr) Composition comprenant un peptide vgll1 pour le traitement du cancer
IL304221A (en) A method for treating chronic kidney diseases
EP3958972A4 (fr) Médicament thérapeutique pour la dyskinésie
EP3897602A4 (fr) Associations pharmaceutiques pour le traitement du cancer
EP4531768A4 (fr) Châssis pour corps supérieur
EP4190340A4 (fr) Médicament thérapeutique ou médicament de diagnostic pour le cancer
HK40117095A (en) Methods for treating anemia of kidney disease
FR2875404B1 (fr) Composition pharmaceutique pour le traitement de la rosacee